In single-arm, open-label, multicenter, phase 3 trials, subcutaneous once-daily setmelanotide was evaluated for efficacy and safety in individuals with severe obesity due to either POMC deficiency or LEPR deficiency [49]. This evidence concerns the gene LEPR and hyperinsulinemic hypoglycemia, familial, 4.